0001193125-22-114263.txt : 20220422 0001193125-22-114263.hdr.sgml : 20220422 20220422082354 ACCESSION NUMBER: 0001193125-22-114263 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220421 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant FILED AS OF DATE: 20220422 DATE AS OF CHANGE: 20220422 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Savara Inc CENTRAL INDEX KEY: 0001160308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841318182 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32157 FILM NUMBER: 22843501 BUSINESS ADDRESS: STREET 1: 6836 BEE CAVE ROAD STREET 2: BUILDING 3, SUITE 201 CITY: AUSTIN STATE: TX ZIP: 78746 BUSINESS PHONE: 51285113796 MAIL ADDRESS: STREET 1: 6836 BEE CAVE ROAD STREET 2: BUILDING 3, SUITE 201 CITY: AUSTIN STATE: TX ZIP: 78746 FORMER COMPANY: FORMER CONFORMED NAME: Mast Therapeutics, Inc. DATE OF NAME CHANGE: 20130312 FORMER COMPANY: FORMER CONFORMED NAME: ADVENTRX PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030613 FORMER COMPANY: FORMER CONFORMED NAME: BIOKEYS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010928 8-K 1 d356716d8k.htm 8-K 8-K
Savara Inc false 0001160308 0001160308 2022-04-21 2022-04-21

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

April 21, 2022

 

 

SAVARA INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-32157   84-1318182

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

6836 Bee Cave Road, Building III, Suite 201

Austin, TX 78746

(Address of principal executive offices, including zip code)

(512) 614-1848

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   SVRA   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 1.01.

Entry into a Material Definitive Agreement.

On April 21, 2022, Savara Inc. (the “Company”) and its subsidiary, Aravas Inc. (“Aravas”), entered into an Amended and Restated Loan and Security Agreement (the “SVB Loan Agreement”) between the Company and Aravas, as co-borrowers, and Silicon Valley Bank, as lender (the “Lender”), which amended and restated in its entirety that certain Loan and Security Agreement between the Company and Aravas, as co-borrowers, and the Lender dated April 28, 2017, as subsequently amended on October 31, 2017, December 4, 2018, January 31, 2020, and March 30, 2021 (the “Prior Agreement”).

The SVB Loan Agreement provides for a $26.5 million term loan facility, the proceeds of which will be used to refinance all outstanding obligations under the Prior Agreement.

Pursuant to the SVB Loan Agreement, the loan has an interest-only monthly payment through April 21, 2026 (the “Interest-Only Period”) and thereafter equal monthly installments of principal plus interest over 12 months until April 21, 2027 (the “Maturity Date”). However, the Company may elect to extend the Interest-Only Period until the Maturity Date if it maintains cash and cash equivalents equal to at least 1.75 times the outstanding principal amount of the loan during the fifth year. If the Interest-Only Period is extended, all principal and unpaid interest is due and payable on the Maturity Date.

The loan bears interest at a floating rate equal to the greater of (i) 3% and (i) the prime rate reported in The Wall Street Journal, minus a spread of 0.5%. Savara is obligated to pay customary closing fees and a final payment of 2.75% of the principal amount advanced under the facility. The Company may prepay the loan in whole or in part at any time, subject to a prepayment fee of 4.25% if prepaid within the first anniversary of the closing date and 1.0% if prepaid between the first and second anniversaries of the closing date. Following the second anniversary, there is no prepayment fee.

The obligations of the Company are secured by substantially all of the Company’s assets, excluding intellectual property and subject to certain other exceptions and limitations.

The SVB Loan Agreement contains customary affirmative and negative covenants, including among others, covenants limiting the ability of the Company and its subsidiaries to dispose of assets, permit a change in control, merge or consolidate, make acquisitions, incur indebtedness, grant liens, make investments, make certain restricted payments and enter into transactions with affiliates, in each case subject to certain exceptions. Additionally, the SVB Loan Agreement contains an affirmative covenant providing that if the Company’s balance of cash and cash equivalents falls below $40 million, the Company is required to maintain cash and cash equivalents equal to at least (i) six months of operating expenses and (ii) 1.2 times the outstanding principal amount of the loan (or 1.75 in the final year of the loan if the Interest-Only Period is extended).


Upon an event of default, the Lender may declare the outstanding obligations payable by the Company to be immediately due and payable and exercise other rights and remedies provided for under the SVB Loan Agreement. The events of default under the SVB Loan Agreement include, among others, payment defaults, covenant defaults, a material adverse change default, bankruptcy and insolvency defaults, cross-defaults to other material indebtedness, judgment defaults, and defaults related to inaccuracy of representations and warranties. Under certain circumstances, a default interest rate will apply on all obligations during the existence of an event of default under the SVB Loan Agreement at a per annum rate of interest equal to 5.0% above the applicable interest rate.

The Lender and its affiliates have engaged in, and may in the future engage in, banking and other commercial dealings in the ordinary course of business with the Company or the Company’s affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions.

The foregoing description of the SVB Loan Agreement is qualified in its entirety by reference to the full text of the SVB Loan Agreement which the Company plans to file with its Form 10-Q for the period ended March 31, 2022.

 

Item 2.03.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth under Item 1.01, “Entry into a Material Definitive Agreement,” under the caption “Loan and Security Agreement,” is incorporated herein by reference.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 22, 2022

      SAVARA INC.
a Delaware corporation
    By:  

/s/ Dave Lowrance

     

Dave Lowrance

Chief Financial Officer

EX-101.SCH 2 svra-20220421.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 svra-20220421_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 svra-20220421_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Apr. 21, 2022
Cover [Abstract]  
Entity Registrant Name Savara Inc
Amendment Flag false
Entity Central Index Key 0001160308
Document Type 8-K
Document Period End Date Apr. 21, 2022
Entity Incorporation State Country Code DE
Entity File Number 001-32157
Entity Tax Identification Number 84-1318182
Entity Address, Address Line One 6836 Bee Cave Road
Entity Address, Address Line Two Building III
Entity Address, Address Line Three Suite 201
Entity Address, City or Town Austin
Entity Address, State or Province TX
Entity Address, Postal Zip Code 78746
City Area Code (512)
Local Phone Number 614-1848
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol SVRA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 d356716d8k_htm.xml IDEA: XBRL DOCUMENT 0001160308 2022-04-21 2022-04-21 Savara Inc false 0001160308 8-K 2022-04-21 DE 001-32157 84-1318182 6836 Bee Cave Road Building III Suite 201 Austin TX 78746 (512) 614-1848 false false false false Common Stock, par value $0.001 per share SVRA NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d356716d8k.htm svra-20220421.xsd svra-20220421_lab.xml svra-20220421_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d356716d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d356716d8k.htm" ] }, "labelLink": { "local": [ "svra-20220421_lab.xml" ] }, "presentationLink": { "local": [ "svra-20220421_pre.xml" ] }, "schema": { "local": [ "svra-20220421.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "svra", "nsuri": "http://www.savarapharma.com/20220421", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d356716d8k.htm", "contextRef": "duration_2022-04-21_to_2022-04-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d356716d8k.htm", "contextRef": "duration_2022-04-21_to_2022-04-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.savarapharma.com//20220421/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001193125-22-114263-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-114263-xbrl.zip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end